Because apparent clearance was 3441% lower in the youngest/lightest children, a weight-based (mg/kg) regimen was selected to achieve comparable systemic exposure across all ages and weights and for getting the target (about 4073% across bands) compared to placebo
Prolonged room-temperature storage degrades the amino acids even when the liquid still looks normal
GLP-1 therapy is particularly considered in patients with a BMI 35 kg/m or those who would benefit from weight loss
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity - Diabetes, Obesity & Metabolism Dosing schedule - Ozempic Once-Weekly Semaglutide in Adults with Overweight or Obesity - New England Journal of Medicine Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity - JAMA Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial - Lancet
Despite these promising benefits, the FDA's decision to scrutinize BPC-157 is based on several key factors